Chronic Total Occlusion Market Report: Size, Share and Outlook by 2031

The Chronic Total Occlusion market is anticipated to grow from US$ 2.44 billion in 2024 and is projected to reach US$ 4.22 billion by 2031; it is expected to register a CAGR of 8.2% during 2025-2031. increasing aging population and the rising prevalence of cardiovascular diseases are contributing to the growing chronic total occlusion market size. However, the high cost of occlusion devices hampers the chronic total occlusion market growth. Further, technological advancements in CTO devices is expected to bring in new chronic total occlusion market trends in the coming years.

In terms of revenue, North America dominated the market in 2024. It is estimated to dominate the global market during the forecast period. The US is the largest market for chronic total occlusion in the world.

The US chronic total occlusion market is growing with the rising incidence of CVD, especially Coronary Artery Disease (CAD), in the aging population. The American Heart Association's (AHA) 2023 Heart Disease and Stroke Statistics Update mentions that approximately 18.2 million adults in the country had CAD. The adoption of minimally invasive methods, including percutaneous coronary intervention (PCI), and the development of sophisticated CTO-specific devices are the major driving forces for market growth. Global leaders such as Medtronic, Boston Scientific, Abbott Laboratories, and Philips Healthcare dominate the US market with their innovative devices and technologies for CTO procedures. The strong healthcare infrastructure, reimbursement policies, and emphasis on enhancing patient outcomes fuel market growth. The growing number of specialized centers and well-trained cardiologists favor the application of CTO procedures. As per the Division of Occupational Employment and Wage Statistics, there were 15,190 employed cardiologists in the US as of 2023. In addition, growing consciousness about cardiovascular health and detection of CTO at an early stage fuel the demand for these interventions.

Chronic Total Occlusion Market Analysis

Strategic Initiatives by Market Players to Provide Market Opportunities in Future

Companies operating in the CTO market constantly focus on strategic developments such as product approvals, collaborations, funding, agreements, and new product launches, which help them improve their sales, increase their geographic reach, and reinforce their capacities to cater to a greater than existing customer base. A few strategic initiatives by key players operating in the CTO market are mentioned below.

- In February 2022, Teleflex Incorporated announced that the U.S. Food and Drug Administration (FDA) granted expanded indications for its specialty catheters and coronary guidewires, specifically for use in chronic total occlusion percutaneous coronary interventions (CTO PCI).

- In June 2024, MicroPort RotaPace's Intravascular Piezoelectric Guidewire System gained NMPA approval for entry into the special review procedures for innovative medical devices. This system was co-developed by a team led by Academician Junbo Ge from Zhongshan Hospital, Fudan University.

- In February 2024, BIOTRONIK introduced the Micro Rx catheter, a novel rapid exchange microcatheter developed to easily enhance guidewire support during PCI. The Micro Rx catheter is the fourth IMDS product that BIOTRONIK has introduced to the US market, contributing to a strong portfolio of devices, which includes the NHancer Rx, TrapIT, and ReCross catheters.

- In October 2022, the FDA-approved NovaCross line of microcatheters (NovaCross BTK for below-the-knee treatment, NovaCross Xtreme for chronic total occlusion treatment, and NovaCross CTO for chronic total occlusion treatment) was among the assets that Microbot Medical Inc. purchased from Nitiloop Ltd. The NovaCross devices are designed to make it easier to implant conventional and steerable guidewires intraluminally beyond stenotic lesions, including chronic complete occlusions, prior to percutaneous transluminal coronary angioplasty or stent intervention.

- In April 2022, the FDA approved Transit Scientific's XO Cross Support Catheter Platform for coronary usage. The platform is intended to facilitate wire exchanges, guide and maintain a guidewire during access to the peripheral or coronary arteries, and serve as a conduit for the administration of diagnostic contrast agents or saline solutions.

- In February 2022, the FDA approved an additional indication for Teleflex Incorporated's specialized catheters and coronary guidewires to be used in crossing chronic complete occlusion (CTO) during percutaneous coronary intervention (PCI).

- In September 2023, Avinger, Inc. announced the full commercial launch of its Tigereye ST next-generation image-guided CTO crossing system. With the initiation of a full commercial launch, all current and prospective accounts can now order the Tigereye ST device.

Therefore, product launches, approvals, and collaborations are expected to create ample opportunities for the growth of the chronic complete occlusion (CTO) market in the coming years.

Chronic Total Occlusion Market Report Segmentation Analysis

Key segments that contributed to the derivation of the chronic total occlusion market analysis are equipment and end user.

- Based on equipment, the chronic total occlusion market is segmented into guide wires, micro catheters, crossing devices, re-entry devices, and others. The guide wires segment held the largest share of the market in 2024.

- In terms of end user, the chronic total occlusion market is categorized into hospitals, ambulatory care centers, and others. The hospitals segment dominated the market in 2024.

Chronic Total Occlusion Market: Competitive Landscape and Key Developments

Asahi Intecc Co Ltd, Cordis Corp, Integer Holdings Corp, Boston Scientific Corp, Becton Dickinson and Co, SoundBite Medical Solutions, Medtronic Plc, Terumo Corp, Abbott, and Koninklijke Philips NV are among the key companies operating in the chronic total occlusion market.

US Census Bureau, World Health Organization (WHO), British Heart Foundation, French National Institute for Demographic Studies, National Institute of Statistics (NIS), National Library of Medicine, National Crime Records Bureau (NCRB), and National Center for Biotechnology Information are among the primary and secondary sources referred to while preparing the chronic total occlusion market report.